Biological determinants of responsiveness to growth hormone: pharmacogenomics and personalized medicine.
It is becoming most clear that many genes are involved in controlling the regulation of growth. Ultimately however, at the level of growth hormone (GH), the relevant question may be not whether a patient is GH-deficient, but whether he is GH-responsive. As these disturbances can be divided into two gross categories, namely alterations causing subnormal GH secretion and/or those presenting with subnormal GH sensitivity/responsiveness, the main aim of this review is to focus on genes involved in growth regulation leading to short stature caused by an alteration of GH insensitivity/GH responsiveness; in other words, clinical circumstances where individually adapted GH replacement therapy may help to increase height velocity and eventually final height.
Paediatric Endocrinology, Diabetology and Metabolism, University Children's Hospital, Inselspital, Bern, Switzerland.
Primus-E
PE
Mullis
D002648:Child; D006130:Growth Disorders / Q000235:genetics* / Q000628:therapy*; D019382:Human Growth Hormone / Q000627:therapeutic use*; D006801:Humans; D010597:Pharmacogenetics / Q000379:methods*; D057285:Precision Medicine / Q000379:methods*
D019382:Human Growth Hormone